Skip to main content

Table 2 Association of antidepressant with risk of significant fibrosis or cirrhosis by weighted regression

From: Association between antidepressant use and liver fibrosis in patients with type 2 diabetes: a population based study

Variables

Significant fibrosis (≥ F2)

Cirrhosis (F4)

 

OR

95%CI

P-value

OR

95%CI

P-value

Sex

1.3

0.27–6.35

0.64

1.29

0.38–4.98

0.79

Age

1.01

0.99–1.04

0.34

1.01

0.98–1.05

0.68

Race

-

-

-

-

-

-

Non-Hispanic white

Ref

-

-

Ref

-

 

Non-Hispanic Black

0.63

0.53–0.91

0.03

1.44

0.99–1.99

0.25

Mexican American

1.82

0.87–3.80

0.11

1.55

0.75–3.20

0.23

Other

1.95

0.21–3.13

0.19

1.75

0.98–2.77

0.2

BMI

1.14

1.1–1.18

0.001

1.17

1.08–1.26

0.01

ALT

0.99

0.94–1.04

0.99

0.87

0.79–1.96

0.21

AST

1.2

1.01–1.03

0.03

1.01

1.01–1.02

0.05

GGT

1.01

1.00–1.03

0.1

1.01

1.00–1.01

0.09

HbA1c

1.1

0.97–1.24

0.20

1.09

0.91–1.38

0.5

Triglycerides

1.02

1.01–1.04

0.04

0.99

0.99–1.00

0.99

LDL

1.08

0.73–1.6

0.68

0.98

0.96–1.01

0.19

Antidepressant use

0.53

0.2–1.58

0.31

0.49

0.07–2.41

0.51

  1. BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transpeptidase, LDL low density lipoprotein, HbA1c glycosylated hemoglobin